Zortix matched this thesis to Biotech ETFs as one way for retail investors to get exposure. Not a recommendation.
First human trial of Yamanaka factors begins
David Friedberg reported that Life Biosciences has begun the first human clinical trial to deliver Yamanaka factors - proteins that can reverse cellular aging - into the eye to treat blindness from conditions like glaucoma.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.